Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11855411 | 0.68 | CYP2C9 (0.42) | CYP2C9ATMMAOAMAOBNISCH | |
| SCHEMBL11781441 | 0.66 | CYP2C9 (0.44) | CYP2C9ATMMAOAMAOBNISCH | |
| SCHEMBL40368 | 0.66 | CYP2C9 (0.55) | CYP2C9ATMMAOAMAOBNISCH | |
| SCHEMBL2885668 | 0.65 | HTT (0.45) | CYP2C9ATMMAOAMAOBMEN1 | |
| SCHEMBL7144469 | 0.65 | NISCH (0.40) | CYP2C9ATMMAOAMAOBNISCH | |
| SCHEMBL831081 | 0.65 | MAOA (0.37) | CYP2C9ATMMAOAMAOBNISCH | |
| SCHEMBL9407337 | 0.65 | AHR (0.46) | CYP2C9ATMMAOAMAOBNISCH | |
| SCHEMBL5475173 | 0.65 | CYP2C9 (0.46) | CYP2C9ATMMAOAMAOBNISCH | |
| SCHEMBL2736398 | 0.64 | MAOA (0.52) | CYP2C9ATMMAOAMAOBNISCH | |
| SCHEMBL501810 | 0.64 | GAA (0.65) | CYP2C9ATMMAOAMAOBNISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915280-B2 | Compounds and their uses | EISAI INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1339402-B1 | AZAPHENANTHRIDONE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | EISAI INC (US) | 2010-08-25 | — | — | EP | disclosed |
| US-RE41150-E1 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | EISAI CORPORATION OF NORTH AMERICA (US) | 2010-02-23 | — | — | US | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7235557-B2 | Compounds and their uses | MGI GP, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7157452-B2 | Substituted 4,9-dihydrocyclopenta{imn}phenanthridine-5-ones derivatives thereof and their uses | MGI GP, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060142266-A1 | Compounds and their uses | MGI GP, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-20060003987-A1 | Compounds and their uses | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | GUILFORD PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6887996-B2 | Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one | GUILFORD PHARMACEUTICALS INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040254372-A1 | Compounds, derivatives, compositions, preparation and uses | EISAI INC. | 2004-12-16 | — | — | US | disclosed |
| US-6545011-B2 | PARP (poly(adenosine 5'-diphospho-ribose) polymerase) inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-04-08 | — | — | US | disclosed |
| US-20030022883-A1 | Compounds and their use | EISAI INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020037904-A1 | Substituted 4,9-dihydrocyclopent a [imn] phenanthridine-5-ones, derivatives thereof and their uses | EISAI INC. | 2002-03-28 | — | — | US | disclosed |
| US-6348475-B1 | POLYMERASE INHIBITOR | GUILFORD PHARMACEUTICALS INC. | 2002-02-19 | — | — | US | disclosed |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | EISAI INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022883-A1 | Compounds and their use | PARP1, PARP2, PARP3 | TRPA1 4152/4885CYP2C9 1908/4885ATM 210/4885 |
| US-20040254372-A1 | Compounds, derivatives, compositions, preparation and uses | PARP1, PARP2, PARP3 | TRPA1 4259/4885CYP2C9 1952/4885ATM 237/4885 |
| US-20060003987-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | TRPA1 4345/4885CYP2C9 2329/4885ATM 233/4885 |
| US-20050148575-A1 | (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury | PARP1, PARP11, PARP15 | TRPA1 1904/4885CYP2C9 1385/4885ATM 750/4885 |
| US-20060142266-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | TRPA1 4345/4885CYP2C9 2329/4885ATM 233/4885 |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | PARP2, PARP1, PARP3 | TRPA1 4021/4885CYP2C9 1326/4885ATM 1750/4885 |
| US-20020037904-A1 | Substituted 4,9-dihydrocyclopent a [imn] phenanthridine-5-ones, derivatives thereof and their uses | PARP1, PARP2, PARP4 | TRPA1 4085/4885CYP2C9 1456/4885ATM 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.